The Journal of Urology
Volume 183, Issue 6 , Pages 2143-2147 , June 2010

Fuhrman Grade Provides Higher Prognostic Accuracy Than Nucleolar Grade for Papillary Renal Cell Carcinoma

  • Tobias Klatte

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Christine Anterasian

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Jonathan W. Said

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Department of Pathology and Laboratory Medicine, University of California-Los Angeles, Los Angeles, California
    • ,
  • Michela de Martino

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Fairooz F. Kabbinavar

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Department of Medicine, University of California-Los Angeles, Los Angeles, California
    • ,
  • Arie S. Belldegrun

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • ,
  • Allan J. Pantuck

      Affiliations

    • Department of Urology, University of California-Los Angeles, Los Angeles, California
    • Corresponding Author InformationCorrespondence: Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, 10833 Le Conte Ave., Room B7-298A CHS, Los Angeles, California 90025-1738 (telephone: 310-206-2436; FAX: 310-794-3513)

Received 8 October 2009

References 

  1. Srigley JR, Hutter RVP, Gelb AB, et al. Current prognostic factors—renal cell carcinoma—Workgroup No. 4. Cancer. 1997;80:994
  2. Gelb AB. Renal cell carcinoma—current prognostic factors. Cancer. 1997;80:981
  3. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol. 2009;22(suppl.):S24
  4. Tickoo SK, Gopalan A. Pathologic features of renal cortical tumors. Urol Clin North Am. 2008;35:551
  5. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655
  6. Goldstein NS. The current state of renal cell carcinoma grading. Cancer. 1997;80:977
  7. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612
  8. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763
  9. Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005;103:68
  10. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131
  11. Eble JN, Togashi K, Pisani P. Tumours of the kidney. In:  Eble JN,  Sauter G,  Epstein JI, et al. editor. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004;p. 9–87chapt 1
  12. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090
  13. Sika-Paotonu D, Bethwaite PB, McCredie MR, et al. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol. 2006;30:1091
  14. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol. 2007;31:957
  15. Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590
  16. Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15:1162
  17. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69:230
  18. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537
  19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649
  20. Leroy X, Zini L, Buob D, et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. Arch Pathol Lab Med. 2007;131:102
  21. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523
  22. Méjean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol. 2003;170:764
  23. Gontero P, Ceratti G, Guglielmetti S, et al. Prognostic factors in a prospective series of papillary renal cell carcinoma. BJU Int. 2008;102:697
  24. Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 2008;102:1381
  25. Lohse CM, Blute ML, Zincke H, et al. Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol. 2002;118:877
  26. Novara G, Martignoni G, Artibani W, et al. Grading systems in renal cell carcinoma. J Urol. 2007;177:430
  27. Lam JS, Klatte T, Kim HL, et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008;65:235
  28. Visapää H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61:845
  29. Klatte T, Seligson DB, Larochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:894

 Study received institutional review board approval.

PII: S0022-5347(10)00264-8

doi: 10.1016/j.juro.2010.02.023

The Journal of Urology
Volume 183, Issue 6 , Pages 2143-2147 , June 2010

Article Tools

* Image Usage & Resolution